Indications
Victrelis is indicated for the treatment of chronic hepatitis-C (CHC) genotype-1 infection, in combination with peginterferon alfa and ribavirin, in adult patients with compensated liver disease who are previously untreated or who have failed previous therapy.
Composition
- Active substance
- Boceprevir
Official product information
The European public assessment report holds the summary of product characteristics and the package leaflet in every EU language.
Prognia shows this product information for reference and learning. It is not treatment advice and can lag behind the official text. Always check the current product information and local protocols before prescribing.
At a glance
- Medicine
- Victrelis
- Active substance
- Boceprevir
- ATC code
- J05AE
- Therapeutic area
- Hepatitis C, Chronic
- Marketing authorisation holder
- Merck Sharp Dohme Ltd
- Status
- Withdrawn